← Leaderboards
Terry D. Connell
State University Of New York At Buffalo
$5,460,672
Attributed
$5,460,672
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $634.7K · FY2005–21$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$5,460,672 · 7
By mechanism
R01$3,236,853 · 1
R21$1,262,259 · 3
K02$526,014 · 1
R56$317,000 · 1
R29$118,546 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Enterotoxins”
- David Heimbrook · Leidos Biomedical Research, Inc.$21,781,988
- Larry Zeitlin · Epicyte Pharmaceutical, Inc.$16,115,050
- W Allan Walker · Harvard University (Medical School)$13,913,743
- Janko Nikolich-Zugich · University Of Arizona$13,812,904
- M. Javad Aman · University Of California San Diego$9,779,606
- Bruce A Mc Clane · University Of Pittsburgh At Pittsburgh$9,361,922
Research focus
EnterotoxinsImmunomodulatorsEscherichia ColiMutantImmunizationFlow CytometryCholera ToxinGangliosidesStreptococcus MutansResponseCellsImmunoregulationImmuneEngineeringAdjuvantCytokineLaboratory MouseExhibitsAffinityAntigensChimeric ProteinsLymphocyteImmune ResponseMucous Membrane
Grant awards (25)
Identification of new ribosylation-dependent immunoregulatory factors$239,250
R21 · FY2021 · AI · contact PI
Identification of new ribosylation-dependent immunoregulatory factors$199,375
R21 · FY2020 · AI · contact PI
Specific induction of lethal autophagy in triple-negative breast cancer cells$211,553
R21 · FY2018 · CA · contact PI
Specific induction of lethal autophagy in triple-negative breast cancer cells$173,456
R21 · FY2017 · CA · contact PI
Safe mucosal vaccines$239,250
R21 · FY2016 · DE · contact PI
Safe mucosal vaccines$199,375
R21 · FY2015 · DE · contact PI
Type II enterotoxins as mucosal immunomodulators$317,000
R56 · FY2011 · DE · contact PI
Type II enterotoxins as mucosal immunomodulators$339,287
R01 · FY2010 · DE · contact PI
Type II enterotoxins as mucosal immunomodulators$342,715
R01 · FY2009 · DE · contact PI
Type II enterotoxins as mucosal immunomodulators$291,952
R01 · FY2009 · DE · contact PI
Type II enterotoxins as mucosal immunomodulators$342,715
R01 · FY2008 · DE · contact PI
Type II enterotoxins as mucosal immunomodulators$346,527
R01 · FY2007 · DE · contact PI
Type II enterotoxins as mucosal immunomodulators$356,877
R01 · FY2006 · DE · contact PI
Mechanisms of Adjuvant Stimulation$105,676
K02 · FY2006 · DE · contact PI
Mechanisms of Adjuvant Stimulation$105,224
K02 · FY2005 · DE
TYPE II Enterotoxins as Mucosal Immunomodulators$298,504
R01 · FY2004 · DE
Mechanisms of Adjuvant Stimulation$104,616
K02 · FY2004 · DE
TYPE II Enterotoxins as Mucosal Immunomodulators$298,189
R01 · FY2003 · DE
Mechanisms of Adjuvant Stimulation$105,117
K02 · FY2003 · DE
TYPE II Enterotoxins as Mucosal Immunomodulators$300,581
R01 · FY2002 · DE
Mechanisms of Adjuvant Stimulation$105,381
K02 · FY2002 · DE
TYPE II Enterotoxins as Mucosal Immunomodulators$12,000
R01 · FY2002 · DE
TYPE II Enterotoxins as Mucosal Immunomodulators$3,981
R01 · FY2002 · DE
TYPE II Enterotoxins as Mucosal Immunomodulators$303,525
R01 · FY2001 · DE
EXTRACELLULAR SECRETION IN VIBRIO CHOLERAE$118,546
R29 · FY2000 · AI